ST.
PAUL, Minn., Jan. 10, 2024 /PRNewswire/ -- 3M Health
Care's Medical Solutions Division, the world leader in
advanced wound care, was awarded $34.2
million from the U.S. Army Medical Research Acquisition
Activity to develop a range of new solutions for infection
prevention, wound management and wound healing. 3M will lead a
program focused on treatment strategies that can be used in austere
settings, especially those related to mass casualty and delayed
evacuation situations -- a critical objective of the Department of
Defense Combat Casualty Care Capability Assessment. In addition,
the program will work to assess biofilm control, biomarker
monitoring and healing in acute trauma situations such as blasts,
burns, and gunshot wounds that occur in civilian and military
settings.
3M will collaborate
with the University of Minnesota
Medical School, the 59th Medical Wing Science &
Technology Office of the Chief Scientist (59MDW/ST, lead military
partner), Naval Medical Research Unit-San Antonio (NAMRU-SA) and
The University of Texas Health Science
Center at San Antonio (UT Health
San Antonio) in this program. The awarded funding will support four
separate product solutions, with studies that range from prototype
and formulation development to completion of two clinical studies
to be used for product registration.
"Successful treatment of acute, traumatic wounds
requires a continuum of care that begins with easy-to-use dressings
and effective infection prevention that can be applied at the point
of injury, continues with portable solutions for transport, and
transitions to more sophisticated solutions in hospital settings
suitable for rehabilitation and reintegration of patients," said
Raymond Chiu, senior vice president,
research & development, 3M Health
Care Business Group. "3M is
proud to be working with civilian and military partners to bring
these solutions to fruition."
The planned work involves at least six principal
investigators leading studies at three different sites across the
United States. Over 125 support personnel will be involved in
the research efforts to be performed over the FY 2023 – FY 2027
award period.
Addressing and stabilizing traumatic injuries in
the field requires fast, effective and easy-to-use solutions that
provide more capability at the point of injury. The novel
solutions developed and demonstrated in this program will also be
well suited for use in civilian traumatic, burn and chronic wound
care.
The U.S. Army Medical Research Acquisition
Activity, 808 Schreider Street, Fort
Detrick MD 21702-5014 is the awarding and administering
acquisition office. In conducting research using animals, the
investigator(s) adheres to the laws of the United States and regulations of the
Department of Agriculture. This work [is] was supported by the
Office of the Assistant Secretary of Defense for Health Affairs, in
the amount of $34,191,124, through
the Defense Health Agency Expeditionary Medicine Research and
Development Program under Award No. HT94252320059. Opinions,
interpretations, conclusions and recommendations are those of the
author and are not necessarily endorsed by the Department of
Defense.
About 3M
3M (NYSE: MMM) believes science helps create a brighter world
for everyone. By unlocking the power of people, ideas and science
to reimagine what's possible, our global team uniquely
addresses the opportunities and challenges of our
customers, communities, and planet. Learn how we're working to
improve lives and make what's next at 3M.com/news.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/3m-receives-34-2-million-award-to-improve-treatment-of-traumatic-wounds-from-point-of-injury-to-hospital-302029025.html
SOURCE 3M Company